Clinical Trials

  • A sign reads "AstraZeneca" with the company logo on an all-glass-grided building facade.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer

    The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.

    By • Oct. 6, 2025
  • An illustration of the collapse of a stock price
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Skye shares crash as obesity drug falls short in key study

    The findings are the latest setback for weight loss medicines that target a specific cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.

    By • Oct. 6, 2025
  • Brain scans of a person with Alzheimer's are seen in this conceptual image. Explore the Trendline➔
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Trendline

    Neuroscience drug development

    Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.

    By BioPharma Dive staff
  • Confident african American male boss work cooperate with diverse team at office briefing
    Image attribution tooltip

    shutterstock.com/fizkes

    Image attribution tooltip
    Sponsored by 1nHealth

    The advantage of engaging patient recruitment partners as strategic allies, not emergency backups

    The secret to on-time trials? Engaging recruitment partners early.

    By Ryan Day and Steve Wimmer • Oct. 6, 2025
  • The exterior of Amgen's office building in South San Francisco, with a sculpted company sign in the foreground and leafless trees on a grassy lawn.
    Image attribution tooltip
    Alamy
    Image attribution tooltip

    Amgen claims ‘landmark’ study result that could widen heart drug’s use

    In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population. 

    By • Oct. 2, 2025
  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Metsera strengthens case for Pfizer buyout with latest study data

    In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing of Eli Lilly’s Zepbound.

    By • Sept. 30, 2025
  • A photo of a declining stock price.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Moonlake shares crash on mixed study results for immune drug

    Anticipated late-stage results in the skin disease hidradenitis suppurativa were described by analysts as “disappointing” and “undifferentiated,” erasing more than four-fifths of the company’s market value.

    By • Sept. 29, 2025
  • A flag flies above the headquarters campus of Eli Lilly
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly stops trial of muscle-sparing obesity drug

    Lilly’s decision comes as the FDA has indicated potentially higher approval standards for drugs meant to preserve muscle in people taking weight loss medicines. 

    By • Sept. 25, 2025
  • A person sits at a table and pours pills into there hand.
    Image attribution tooltip
    Permission granted by Michael Sage
    Image attribution tooltip
    Deep Dive // Pain drugs

    Cancer patients are living longer than ever. Pain drugmakers haven’t kept up.

    Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily pain. Doctors fear that’s bound to continue.

    By • Sept. 25, 2025
  • Employees of biotechnology company UniQure work in a laboratory.
    Image attribution tooltip
    Courtesy of UniQure
    Image attribution tooltip

    UniQure to seek approval of Huntington’s gene therapy after trial win

    New study data showed treatment slowed signs of disease progression by 75% after three years, a finding that could have “massive effects on patients’ lives,” an investigator said.

    By • Sept. 24, 2025
  • A sign for Acadia Pharmaceuticals is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Acadia Pharmaceuticals
    Image attribution tooltip

    Acadia to scrap Prader-Willi drug after study setback

    The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential competitor to Soleno’s fast-selling Vykat. 

    By Kristin Jensen • Sept. 24, 2025
  • A micrograph of a myeloma neoplasm in a bone marrow biopsy.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Bristol Myers says next-gen blood cancer drug hits goal in key study

    The drug, iberdomide, is one of a few protein-degrading medicines the company hopes to become successors to its blockbuster Revlimid franchise.

    By • Sept. 23, 2025
  • Friendly relationship between caregiver and happy eldery person during nursing at home.
    Image attribution tooltip

    Adobe Stock

    Image attribution tooltip
    Sponsored by EmVenio Clinical Research

    Meet the new EmVenio – where science meets people

    EmVenio makes clinical trial participation easier, more inclusive and more reflective of our world.

    By EmVenio Clinical Research • Sept. 22, 2025
  • Close-up on a scientist using a mobile app on a digital tablet while working at the laboratory
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Roivant pill succeeds in rare inflammatory disease trial

    A drug licensed from Pfizer will be submitted to the FDA next year after study results showed it reduced dermatomyositis symptoms and steroid use.

    By • Sept. 17, 2025
  • An illustration of human lungs with a geometrical effect.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    ATyr shares plunge on trial miss in inflammatory lung disease

    The company’s market value was largely wiped out after a therapy it’s been developing for pulmonary sarcoidosis missed its main study goal.

    By • Sept. 15, 2025
  • A large group of dosing pens for subcutaneous injection of anti-obesity medication piled in a heap.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology

    Early academic research suggests various ways weight loss drugs could have an impact in cancer care.

    By Michael Gibney • Sept. 12, 2025
  • This image depicts the podcast series cover image for Pearson's BioPharma Dive series, "The Progress Profile: Alzheimer’s Research in Focus"
    Image attribution tooltip
    William Walker/BioPharma Dive
    Image attribution tooltip
    Sponsored by Pearson

    [Podcast] The Progress Profile: Alzheimer’s Research in Focus

    Discover the latest breakthroughs in Alzheimer's research, diagnosis, and prevention in this expert-led podcast series.

    By BioPharma Dive's studioID • Sept. 10, 2025
  • A BioNTech logo hangs on the side of an office building.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip

    BioNTech says dual-acting lung cancer drug helped shrink tumors

    The Bristol Myers-partnered bispecific antibody kept small cell lung cancer under control in participants enrolled in a Phase 2 trial.

    By • Sept. 8, 2025
  • A brain scan is seen on a computer screen in an empty medical laboratory.
    Image attribution tooltip
    Dragos Condrea via Getty Images
    Image attribution tooltip
    Brain drug revival

    A new class of sleep drugs draws Wall Street’s attention

    Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

    By • Sept. 8, 2025
  • Image attribution tooltip
    Jens Schlueter via Getty Images
    Image attribution tooltip
    Vaccines

    Pfizer, BioNTech showcase new data supporting COVID booster

    The companies said their updated shot spurred an increase in neutralizing antibodies against currently circulating strains, answering calls for more corroborating evidence.

    By • Sept. 8, 2025
  • A medical Illustration showing lung cancer or bronchial carcinoma.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    New Summit data clouds approval pathway in lung cancer

    A combination of ivonescimab and chemo didn’t extend survival over chemo alone in a global trial, missing a key goal often emphasized by regulators.

    By • Sept. 8, 2025
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    Rapport shares double on better-than-expected seizure drug data

    One analysts called the Phase 2 study results a “best-case scenario” for a drug Rapport is developing to treat focal onset seizures.

    By • Sept. 8, 2025
  • Woman about to stand on a weighing scale
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Sponsored by IQVIA Technologies

    How sponsors are staying ahead in the obesity trial landscape

    Aligning digital innovation with thoughtful design is accelerating progress.

    Sept. 8, 2025
  • Doctor works on HUD or graphic display in front of her
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Sponsored by Pfizer

    Harnessing the power of AI to detect ATTR-CM

    From accelerating drug discovery to improving disease detection, AI is transforming the way we understand and manage health.

    Sept. 8, 2025
  • A white sign bears the word Sanofi at a road entrance to an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sanofi’s touted eczema drug hits study goal, but data fall short of expectations

    Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug class once viewed as particularly promising.

    By Kristin Jensen • Sept. 4, 2025
  • A 3D illustration of a ribosome as part of an biological cell constructing a messenger RNA molecule.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Wave shares sink on new study results for RNA editing drug

    Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.  

    By • Sept. 3, 2025